Applied StemCell, Inc., a Milpitas, CA-based gene-editing company, closed a $19m Series D funding round.
The round was led by HerMed Capital with participation from Ping An Ventures, Vi-Ventures and BioSciKin.
The company intends to use the proceeds to accelerate the development of its pipeline, expand its gene editing platform technology, as well as to continue to strengthen its intellectual property portfolio.
Led by Ruhong Jiang, Ph.D., Co-founder and Chief Executive Officer, Applied StemCell is a stem cell and gene-editing company focused on the development of products and therapeutics that are enabled by its proprietary gene editing platform technologies TARGATT™ and CRISPR/Cas9. ASC’s strategy is to expand its IP portfolio and develop a therapeutic pipeline with focus on monogenic blood disorders that are characterized by high genetic penetrance.